MacroGenics, Inc. $MGNX Position Increased by Wasatch Advisors LP

Wasatch Advisors LP grew its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 29.4% during the second quarter, Holdings Channel reports. The firm owned 2,018,881 shares of the biopharmaceutical company’s stock after acquiring an additional 459,180 shares during the quarter. Wasatch Advisors LP’s holdings in MacroGenics were worth $9,327,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of MGNX. R Squared Ltd bought a new stake in shares of MacroGenics during the 4th quarter valued at about $26,000. Engineers Gate Manager LP acquired a new stake in MacroGenics during the second quarter worth about $28,000. Walleye Capital LLC bought a new position in MacroGenics in the second quarter worth about $30,000. Cresset Asset Management LLC lifted its holdings in MacroGenics by 52.3% in the second quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 9,172 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new position in MacroGenics in the second quarter valued at approximately $33,000. 96.89% of the stock is currently owned by institutional investors.

MacroGenics Stock Up 2.6%

Shares of NASDAQ:MGNX opened at $4.02 on Thursday. The company has a market cap of $255.52 million, a PE ratio of -3.65 and a beta of 1.20. The company’s 50-day moving average price is $4.22 and its 200 day moving average price is $3.36. MacroGenics, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $5.08.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.01). MacroGenics had a negative return on equity of 147.80% and a negative net margin of 44.79%.The firm had revenue of $20.77 million during the quarter, compared to the consensus estimate of $15.24 million. As a group, equities analysts anticipate that MacroGenics, Inc. will post -1.76 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays upped their target price on MacroGenics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Monday, April 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of MacroGenics in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MacroGenics has a consensus rating of “Hold” and an average price target of $5.50.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.